JC virus antibody status underestimates infection rates

Annals of Neurology

Volumn 74, Issue 1, 2013, Pages 84-90

  Berger, Joseph R ^a   Houff, Sidney A ^a   Gurwell, Julie ^a   Vega, Nubia ^a   Miller, Craig S ^b   Danaher, Robert J ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY FLUID; COHORT ANALYSIS; FEMALE; GENE DOSAGE; HUMAN; IMMUNOASSAY; INFECTION RATE; JC VIRUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SEROLOGY; URINALYSIS; VIREMIA; VIRUS INFECTION;

ADULT; AGED; AUTOANTIBODIES; DNA, VIRAL; FEMALE; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR VIRUS INFECTIONS; YOUNG ADULT;

EID: 84883284823     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23893     Document Type: Article

References (40)

1. Kleinschmidt-DeMasters BK, Tyler KL,. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
2. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381. et al.
3. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368.
4. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
5. TYSABRI Safety Update. 2012. Available at: https://medinfo.biogenidec. com/medinfo/secure/pmlresource.do?resource=TYSABRIPMLSafetyUpdate Accessed August 20, 2012.
6. Bofill-Mas S, Pina S, Girones R,. Documenting the epidemiologic patterns of polyomaviruses in human populations by studying their presence in urban sewage. Appl Environ Microbiol 2000; 66: 238-245.
7. Berger JR, Miller CS, Mootoor Y, et al. JC virus detection in bodily fluids: Clues to transmission. Clin Infect Dis 2006; 43: e9-e12.
8. Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52: 253-260.
9. Whiley DM, Arden KE, Mackay IM, et al. Simultaneous detection and differentiation of human polyomaviruses JC and BK by a rapid and sensitive PCR-ELAHA assay and a survey of the JCV subtypes within an Australian population. J Med Virol 2004; 72: 467-472.
10. Berger JR, Khalili K,. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 2012; 12: 495-503.
11. Padgett BL, Walker DL,. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127: 467-470.
12. Taguchi F, Kajioka J, Miyamura T,. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982; 26: 1057-1064.
13. Walker D, Padgett B,. The epidemiology of human polyomaviruses. In:, Sever J, Madden D, eds. Polyomaviruses and human neurological disease. New York, NY: Alan R. Liss, 1983: 99-106.
14. Walker D, Padgett B,. Progressive multifocal leukoencephalopathy. In:, Fraenkel-Conrat H, Wagner R, eds. Comprehensive virology. New York, NY: Plenum, 1983: 161-193.
15. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71: 115-123.
16. Matos A, Duque V, Beato S, et al. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 2010; 82: 494-504.
17. Miller CS, Houff SA, Hopper J, et al. Disease modifying drugs for multiple sclerosis and JC virus expression. J Neurovirol 2012; 18: 411-415.
18. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
19. MacKenzie J, Wilson KS, Perry J, et al. Association between simian virus 40 DNA and lymphoma in the United Kingdom. J Natl Cancer Inst 2003; 95: 1001-1003.
20. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-750.
21. Arthur RR, Dagostin S, Shah KV,. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol 1989; 27: 1174-1179.
22. Ryschkewitsch C, Jensen P, Hou J, et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004; 121: 217-221.
23. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9: 264-272.
24. Knowles WA, Luxton RW, Hand JF, et al. The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathy. Clin Diagn Virol 1995; 4: 183-194.
25. Padgett BL, Walker DL,. Virologic and serologic studies of progressive multifocal leukoencephalopathy. Prog Clin Biol Res 1983; 105: 107-117.
26. Weber T, Weber F, Petry H, Luke W,. Immune response in progressive multifocal leukoencephalopathy: an overview. J Neurovirol 2001; 7: 311-317.
27. Guillaume B, Sindic CJ, Weber T,. Progressive multifocal leukoencephalopathy: simultaneous detection of JCV DNA and anti-JCV antibodies in the cerebrospinal fluid. Eur J Neurol 2000; 7: 101-106.
28. Viscidi RP, Khanna N, Tan CS, et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011; 53: 711-715.
29. Lee P, Plavina T, Castro A, et al. An enhanced ELISA for detection of anti-JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. Paper presented at: 22nd Annual Meeting of the European Neurological Society; June 9-12, 2012; Prague, Czech Republic (P467).
30. Etxeberria A, Outteryck O, Ongagna JC, et al. Annual rate of JCV seroconversion in a French cohort of MS patients under natalizumab. In: European Committee for Treatment and Research in Multiple Sclerosis Congress; October 10-13, 2012; Lyon, France (P996).
31. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 2012; 79: 2258-2264.
32. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78: 1736-1742.
33. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO,. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010; 68: 384-391.
34. Goelz SE, Gorelik L, Subramanyam M,. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 2011; 69: 429-430; author reply 430-431.
35. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Eng J Med 2012; 366: 1870-1880.
36. Berger JR, Khalili K,. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 2011; 12: 495-503.
37. Hasan KN, Rumi MA, Hasanat MA, et al. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg/anti-HBe, and liver function tests. Southeast Asian J Trop Med Public Health 2002; 33: 110-117.
38. Kalantar-Zadeh K, Miller LG, Daar ES,. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290-300.
39. Kaufman HE, Azcuy AM, Varnell ED, et al. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 2005; 46: 241-247.
40. Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008; 57: 1393-1397.